JP7162591B2 - スピロピペリジン誘導体 - Google Patents

スピロピペリジン誘導体 Download PDF

Info

Publication number
JP7162591B2
JP7162591B2 JP2019531624A JP2019531624A JP7162591B2 JP 7162591 B2 JP7162591 B2 JP 7162591B2 JP 2019531624 A JP2019531624 A JP 2019531624A JP 2019531624 A JP2019531624 A JP 2019531624A JP 7162591 B2 JP7162591 B2 JP 7162591B2
Authority
JP
Japan
Prior art keywords
spiro
piperidine
carboxamide
quinolyl
chroman
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019531624A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020511412A (ja
JP2020511412A5 (enExample
Inventor
ハドキンス，ロバート，エル．
ホイットマン，デイヴィッド，ビー．
ジフィクサック，クレイグ，エイ．
ズーリ，アリソン，エル．
マクワーター，メロディー
Original Assignee
エイティナイン バイオ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エイティナイン バイオ リミテッド filed Critical エイティナイン バイオ リミテッド
Publication of JP2020511412A publication Critical patent/JP2020511412A/ja
Publication of JP2020511412A5 publication Critical patent/JP2020511412A5/ja
Priority to JP2022129676A priority Critical patent/JP2022166192A/ja
Application granted granted Critical
Publication of JP7162591B2 publication Critical patent/JP7162591B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019531624A 2016-12-14 2017-12-14 スピロピペリジン誘導体 Active JP7162591B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022129676A JP2022166192A (ja) 2016-12-14 2022-08-16 スピロピペリジン誘導体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662434167P 2016-12-14 2016-12-14
US62/434,167 2016-12-14
PCT/US2017/066422 WO2018112204A1 (en) 2016-12-14 2017-12-14 Spiropiperidine derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022129676A Division JP2022166192A (ja) 2016-12-14 2022-08-16 スピロピペリジン誘導体

Publications (3)

Publication Number Publication Date
JP2020511412A JP2020511412A (ja) 2020-04-16
JP2020511412A5 JP2020511412A5 (enExample) 2021-01-28
JP7162591B2 true JP7162591B2 (ja) 2022-10-28

Family

ID=62559235

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019531624A Active JP7162591B2 (ja) 2016-12-14 2017-12-14 スピロピペリジン誘導体
JP2022129676A Pending JP2022166192A (ja) 2016-12-14 2022-08-16 スピロピペリジン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022129676A Pending JP2022166192A (ja) 2016-12-14 2022-08-16 スピロピペリジン誘導体

Country Status (7)

Country Link
US (3) US11046707B2 (enExample)
EP (1) EP3554637A4 (enExample)
JP (2) JP7162591B2 (enExample)
CA (1) CA3046805A1 (enExample)
IL (1) IL267145B (enExample)
MX (1) MX392586B (enExample)
WO (1) WO2018112204A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022166192A (ja) * 2016-12-14 2022-11-01 エイティナイン バイオ リミテッド スピロピペリジン誘導体

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2594188B (en) 2016-04-08 2022-02-09 Phillip Chevalier John Latching systems for latching movable panels
HU231333B1 (hu) * 2018-07-13 2023-01-28 Richter Gedeon Nyrt Spirokromán származékok
HU231414B1 (hu) 2018-07-13 2023-08-28 Richter Gedeon Nyrt. Tiadiazin származékok
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
CN113793910B (zh) * 2021-10-22 2024-11-26 浙江华显光电科技有限公司 有机光电器件及包含其的显示或照明装置

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070117823A1 (en) 2005-11-14 2007-05-24 Solvay Pharmaceuticalss Gmbh N-sulfamoyl-N'-benzopyranpiperidine compounds and uses thereof
JP2009502785A (ja) 2005-07-19 2009-01-29 メルク エンド カムパニー インコーポレーテッド アセチルコエンザイムａカルボキシラーゼ（ａｃｃ）阻害薬としてのスピロクロマノン誘導体
JP2009515928A (ja) 2005-11-14 2009-04-16 ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング カルボニックアンヒドラーゼの阻害剤としてのｎ−スルファモイル−ｎ’−ベンゾピランピペリジン
WO2010002010A1 (en) 2008-07-04 2010-01-07 Banyu Pharmaceutical Co.,Ltd. Novel spirochromanone carboxylic acids
JP2010515733A (ja) 2007-01-12 2010-05-13 メルク・シャープ・エンド・ドーム・コーポレイション 置換スピロクロマノン誘導体
JP2010515734A (ja) 2007-01-12 2010-05-13 メルク・シャープ・エンド・ドーム・コーポレイション スピロクロマノン誘導体
WO2012161119A1 (ja) 2011-05-20 2012-11-29 興和株式会社 新規なスピロピペリジン誘導体及びこれを含有する医薬
CN103304571A (zh) 2012-03-06 2013-09-18 上海昀怡健康管理咨询有限公司 螺环化合物、其制备方法、中间体、药物组合物和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08506817A (ja) 1993-02-12 1996-07-23 メルク エンド カンパニー インコーポレーテッド スピロ（２ｈ−１−ベンゾピラン−２，４′−ピペリジン）クラス▲ｉｉｉ▼抗不整脈薬
MX2010008375A (es) * 2008-01-30 2011-03-04 Cephalon Inc Star Derivados de piperidina espirocíclicos substituidos como ligandos de receptores de histamina-3 (h3).
JP2019531624A (ja) 2016-08-10 2019-10-31 アイディーエーシー ホールディングス インコーポレイテッド 次世代無線システムに対する空間変調
JP7162591B2 (ja) * 2016-12-14 2022-10-28 エイティナイン バイオ リミテッド スピロピペリジン誘導体

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009502785A (ja) 2005-07-19 2009-01-29 メルク エンド カムパニー インコーポレーテッド アセチルコエンザイムａカルボキシラーゼ（ａｃｃ）阻害薬としてのスピロクロマノン誘導体
US20070117823A1 (en) 2005-11-14 2007-05-24 Solvay Pharmaceuticalss Gmbh N-sulfamoyl-N'-benzopyranpiperidine compounds and uses thereof
JP2009515928A (ja) 2005-11-14 2009-04-16 ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング カルボニックアンヒドラーゼの阻害剤としてのｎ−スルファモイル−ｎ’−ベンゾピランピペリジン
JP2010515733A (ja) 2007-01-12 2010-05-13 メルク・シャープ・エンド・ドーム・コーポレイション 置換スピロクロマノン誘導体
JP2010515734A (ja) 2007-01-12 2010-05-13 メルク・シャープ・エンド・ドーム・コーポレイション スピロクロマノン誘導体
WO2010002010A1 (en) 2008-07-04 2010-01-07 Banyu Pharmaceutical Co.,Ltd. Novel spirochromanone carboxylic acids
WO2012161119A1 (ja) 2011-05-20 2012-11-29 興和株式会社 新規なスピロピペリジン誘導体及びこれを含有する医薬
CN103304571A (zh) 2012-03-06 2013-09-18 上海昀怡健康管理咨询有限公司 螺环化合物、其制备方法、中间体、药物组合物和应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHEN,H.C. et al.，Bioorganic & Medicinal Chemistry Letters，2009年，Vol.19，pp.3398-3404

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022166192A (ja) * 2016-12-14 2022-11-01 エイティナイン バイオ リミテッド スピロピペリジン誘導体

Also Published As

Publication number Publication date
JP2020511412A (ja) 2020-04-16
US11878982B2 (en) 2024-01-23
EP3554637A4 (en) 2020-05-20
EP3554637A1 (en) 2019-10-23
US20200031840A1 (en) 2020-01-30
WO2018112204A1 (en) 2018-06-21
US20210284651A1 (en) 2021-09-16
CA3046805A1 (en) 2018-06-21
US12448392B2 (en) 2025-10-21
US20240166661A1 (en) 2024-05-23
MX2019006920A (es) 2019-11-28
MX392586B (es) 2025-03-24
IL267145A (en) 2019-08-29
US11046707B2 (en) 2021-06-29
JP2022166192A (ja) 2022-11-01
IL267145B (en) 2022-01-01

Similar Documents

Publication Publication Date Title
JP7307144B2 (ja) １，４－置換ピペリジン誘導体
JP7162591B2 (ja) スピロピペリジン誘導体
ES2785498T3 (es) Ftalazinonas e isoquinolinonas como inhibidores de ROCK
US12441702B2 (en) Substituted 4-benzyl and 4-benzoyl piperidine derivates
TW201726619A (zh) 作為ｒｏｃｋ抑制劑之螺庚烷水楊酸醯胺及相關化合物
EP4055013A1 (en) Wdr5 inhibitors and modulators
WO2025153096A1 (zh) 细胞周期依赖性激酶降解剂及其制备方法和用途
HK1252794B (en) Substituted 4-benzyl and 4-benzoyl piperidine derivatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211124

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220224

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220420

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220816

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220816

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220816

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220905

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220907

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220928

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221018

R150 Certificate of patent or registration of utility model

Ref document number: 7162591

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350